Patents by Inventor Antonello Pessi

Antonello Pessi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230285514
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: September 14, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • Publication number: 20230270825
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 31, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • Publication number: 20230063794
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • Patent number: 11492385
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: November 8, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Publication number: 20200392196
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Patent number: 10836792
    Abstract: The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, formation of a capillary network, and the entry into bloodstream. They are therefore useful in the treatment of diseases and conditions that are sustained by an increase of cell motility, cell invasion, and/or angiogenesis, such as tumors and chronic inflammation.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 17, 2020
    Assignee: ISTITUTO NAZIONALE TUMORI IRCCS “FONDAZIONE G. PASCALE”
    Inventors: Maria Vincenza Carriero, Gennaro Ciliberto, Katia Bifulco, Antonello Pessi
  • Patent number: 10793615
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Patent number: 10493125
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • Publication number: 20190338008
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 7, 2019
    Inventors: Anandan Palani, Ravi Nargund, Paul E. Carrington, Tomi Sawyer, Qiaolin Deng, Antonello Pessi, Elisabetta Bianchi, Federica Orvieto
  • Patent number: 10413593
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • Publication number: 20190135863
    Abstract: The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, formation of a capillary network, and the entry into bloodstream. They are therefore useful in the treatment of diseases and conditions that are sustained by an increase of cell motility, cell invasion, and/or angiogenesis, such as tumors and chronic inflammation.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 9, 2019
    Applicant: ISTITUTO NAZIONALE TUMORI IRCCS "FONDAZIONE G. PASCALE"
    Inventors: Maria Vincenza Carriero, Gennaro Ciliberto, Katia Bifulco, Antonello Pessi
  • Publication number: 20180339017
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: December 5, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • Publication number: 20170360893
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity
    Type: Application
    Filed: October 22, 2015
    Publication date: December 21, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • Patent number: 9593155
    Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 14, 2017
    Assignees: MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Paul E. Carrington, George J. Eiermann, Donald J. Marsh, Joseph M. Metzger, Alessandro Pocai, Ranabir Sinha Roy, Elisabetta Bianchi, Paolo Ingallinella, Antonello Pessi, Alessia Santoprete, Elena Capito, Richard Dimarchi, Brian Ward
  • Publication number: 20160114000
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: October 22, 2015
    Publication date: April 28, 2016
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • Publication number: 20150307580
    Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
    Type: Application
    Filed: April 14, 2015
    Publication date: October 29, 2015
    Inventors: Paul E. CARRINGTON, George J. EIERMANN, Donald J. MARSH, Joseph M. METZGER, Alessandro POCAI, Ranabir SINHA ROY, Elisabetta BIANCHI, Paolo INGALLINELLA, Antonello PESSI, Alessia PRETE, Elena CAPITO, Richard DIMARCHI, Brian WARD
  • Patent number: 8969294
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: March 3, 2015
    Assignees: Istituto di Recerche di Biologia Molecolare P. Angeletti S.R.L., Indiana University Research and Technology Corporation
    Inventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
  • Publication number: 20140161826
    Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 12, 2014
    Inventor: Antonello Pessi
  • Publication number: 20140094405
    Abstract: The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 3, 2014
    Applicant: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
    Inventors: Antonello PESSI, Elisabetta Bianchi, Paolo Ingallinella
  • Patent number: 8629101
    Abstract: The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: January 14, 2014
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
    Inventors: Antonello Pessi, Elisabetta Bianchi, Paolo Ingallinella